Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNephrologyAetna epoetin-alfa prior auth requirements | OpenP…
    Ask Trek AI about this page
    CurrentAetnaPolicy N/A

    Epoetin-alfa (Epogen/Procrit/Retacrit) precertification request form

    Customize your policy alerts

    Sign up for all Aetna policy alerts

    Know when Aetna releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is Aetna's precertification request form and required clinical information checklist for initiation or continuation of epoetin-alfa (Epogen®, Procrit®, Retacrit®) therapy, intended for prescribers and staff submitting authorization requests.

    Policy Summary
    PayerAetna
    PolicyEpoetin-alfa (Epogen/Procrit/Retacrit) precertification request form
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a fully completed, legible precertification form including patient demographics, prescriber details, product/dose, ICD code(s), TSAT and hemoglobin values/dates, prior ESA use, and signature.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2 pagesform length
    Multipleanemia indications listed
    Phone/Faxprecert contact

    Coverage Criteria and Indication-specific Requirements

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Required clinical criteria for precertification

    Coverage requests are reviewed when required clinical information is provided for the requested indication; different indication-specific details are collected.

    General submission requirements: Form fully completed and legible; product, dose, frequency, primary ICD code(s), pretreatment hemoglobin values and dates (exclude values due to a recent transfusion), TSAT and date, iron therapy status, prior ESA use within 30 days, concomitant ESA use, signature and date.

    Supports precertification review

    Initiation-specific items: If initiation request: assessment for iron deficiency (TSAT) and documentation of TSAT percent and date; indicate whether patient is receiving iron therapy; document whether patient has contraindication, intolerance, or ineffective response to alternative ESAs (e.g., Retacrit, Aranesp) where asked; indicate pretreatment hemoglobin and date.

    Collected for all initiation requests

    Continuation-specific items: If continuation request: documentation that patient completed at least 12 weeks of ESA therapy; TSAT and date; iron therapy status; whether Hgb increased by >= 1 g/dL at any time since start of ESA therapy; current Hgb and date; number of weeks completed.>=12 weeks; Hgb increase >= 1 g/dL

    Required for continuation review

    For presurgical use, the form specifically captures whether the patient is scheduled for an elective, noncardiac, nonvascular surgery when epoetin-alfa is being requested to reduce allogeneic blood transfusions. The form also requires the patient's pretreatment hemoglobin (Hgb) and the date of the test (excluding values influenced by a recent transfusion) to support the presurgical indication.

    The plan may request additional information or clarification as needed to evaluate a precertification request. The form includes an acknowledgment that any person who knowingly submits materially false or misleading information to obtain coverage may be committing a fraudulent insurance act and is subject to criminal and civil penalties.

    Administration Codes and Therapy Metrics

    Administration codesCPT
    Administration code(s) (CPT)Placeholder for administration CPT codes to be provided on form
    ESA therapy duration for continuation
    Continuation duration requirement>= 12 weeks of ESA therapy documented
    Evidence to provideNumber of weeks completed documented on form
    ContextRequired for continuation precertification review
    Hgb response threshold
    Hgb response thresholdIncrease of >= 1 g/dL at any time since start of ESA therapy
    Where documentedChecked on continuation request section ('Has the patient's Hgb increased by 1 g/dL or more?')
    PurposeUsed to assess clinical response for continuation requests

    Precertification Submission Requirements and Provider Notices

    Prior Authorization

    Precertification required

    Precertification is required. Contact Aetna Precertification Notification by phone or fax as listed on the form before initiating therapy.

    • Phone: 1-866-752-7021
    • FAX: 1-888-267-3277
    • For Medicare Advantage Part B: Please use Medicare Request Form
    Documentation Required

    Alternate ESA assessment

    For all initiation requests, document whether the patient has a contraindication, intolerance, or ineffective response to Retacrit (alternate ESA). For CKD and chemotherapy indications, document whether the patient has a contraindication, intolerance, or ineffective response to Aranesp. Include dates and supporting clinical data.

    • Does the patient have a contraindication, intolerance or ineffective response to Retacrit? (Yes/No)
    • Does the patient have a contraindication, intolerance or ineffective response to Aranesp? (Yes/No)
    • For initiation requests: record pretreatment hemoglobin (Hgb) level and date (exclude values due to recent transfusion)
    • For initiation requests: assess iron deficiency — provide most recent TSAT (%) and date, and whether patient is receiving iron therapy
    Documentation Required

    Required documentation on form

    The precertification form must be fully completed and legible. Required elements include patient demographics, insurance information, prescriber and dispensing provider details, and full request-specific clinical information (diagnosis, indication, prior ESA use, hemoglobin and TSAT values with dates, iron therapy status, and product requested).

    • All fields must be completed and legible for precertification review
    • Patient information (name, DOB, contact, allergies, weight/height)
    • Prescriber information (name, credentials, NPI, license, specialty, phone/fax)
    • Product information (Epogen/Procrit/Retacrit, dose, frequency)
    • Diagnosis (primary ICD code and any secondary codes)
    • Clinical info for initiation or continuation requests including prior ESA use within 30 days, pretreatment and current Hgb with dates, TSAT and iron therapy status, and duration/weeks of ESA therapy for continuation requests
    Denial Risk

    Submission risks

    Incomplete or illegible submissions may prevent review. Any person who knowingly submits materially false information or conceals material information may be subject to criminal and civil penalties. The plan may request additional information or clarification if needed to evaluate requests.

    • Incomplete or illegible submissions may delay or prevent precertification review
    • Materially false information or concealment may be considered fraud and is subject to penalties
    • The plan may request additional information or clarification to evaluate requests

    Clinical Background

    Epoetin-alfa (Epogen®, Procrit®, Retacrit®) is an erythropoiesis-stimulating agent (ESA) used to treat anemia associated with multiple conditions. The precertification form lists common indications captured for review, including anemia of chronic kidney disease, chemotherapy-related anemia, myelodysplastic syndromes, anemia related to hepatitis C therapy or zidovudine in HIV, certain cases of rheumatoid arthritis, and specific surgical settings where transfusion reduction is the goal. The form collects baseline data—such as pretreatment Hgb, iron studies (TSAT), and prior ESA exposure—to support medical-necessity review for initiation or continuation of epoetin therapy.

    Initiation and Continuation Request Definitions

    Initiation request requirements
    Iron assessment requiredPatient must be assessed for iron deficiency anemia with TSAT percent and date provided
    Pretreatment HgbProvide patient's pretreatment hemoglobin level and date (exclude values due to recent transfusion)
    Iron therapy statusIndicate whether patient is receiving iron therapy on the initiation section of the form
    Alternative ESA considerationIndicate contraindication/intolerance/ineffective response to alternative ESAs (e.g., Retacrit, Aranesp) as asked
    Continuation request requirements
    Minimum therapy durationDocumentation that patient completed at least 12 weeks of ESA therapy
    TSAT and iron statusProvide most recent serum TSAT level and date, and indicate if receiving iron therapy
    Hgb response and current HgbDocument whether Hgb increased >=1 g/dL since ESA start and provide current Hgb and date
    Weeks completedProvide number of weeks of ESA therapy completed
    Policy Summary
    PayerAetna
    PolicyEpoetin-alfa (Epogen/Procrit/Retacrit) precertification request form
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a fully completed, legible precertification form including patient demographics, prescriber details, product/dose, ICD code(s), TSAT and hemoglobin values/dates, prior ESA use, and signature.
    SourceLink
    On This Page
    Coverage Criteria and Indication-specific RequirementsAdministration Codes and Therapy MetricsPrecertification Submission Requirements and Provider NoticesClinical BackgroundInitiation and Continuation Request Definitions